American Banking and Market News logo

The Latest Headlines at American Banking and Market News

Image about Brooks Macdonald Group (LON:BRK) Given “Buy” Rating at Shore Capital

Brooks Macdonald Group (LON:BRK) Given “Buy” Rating at Shore Capital

Shore Capital reissued their buy rating on shares of Brooks Macdonald Group (LON:BRK – Free Report) in a research report released on Wednesday, MarketBeat reports. Brooks Macdonald Group Trading Up 3.4 % LON:BRK opened at GBX... More of this article »
Image about Deltic Energy’s (DELT) “Speculative Buy” Rating Reaffirmed at Canaccord Genuity Group

Deltic Energy’s (DELT) “Speculative Buy” Rating Reaffirmed at Canaccord Genuity Group

Canaccord Genuity Group reissued their speculative buy rating on shares of Deltic Energy (LON:DELT – Free Report) in a research report report published on Wednesday morning, MarketBeat reports. They currently have a GBX 160... More of this article »
Image about ASOS (LON:ASC) Price Target Lowered to GBX 490 at Berenberg Bank

ASOS (LON:ASC) Price Target Lowered to GBX 490 at Berenberg Bank

ASOS (LON:ASC – Free Report) had its price target reduced by Berenberg Bank from GBX 510 ($6.35) to GBX 490 ($6.10) in a research report report published on Wednesday, MarketBeat Ratings reports. They currently have a buy rating... More of this article »
Image about B&M European Value Retail (LON:BME) Receives “Buy” Rating from Deutsche Bank Aktiengesellschaft

B&M European Value Retail (LON:BME) Receives “Buy” Rating from Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their buy rating on shares of B&M European Value Retail (LON:BME – Free Report) in a research note issued to investors on Wednesday morning, Marketbeat reports. Deutsche Bank... More of this article »
Image about Wix.com (NASDAQ:WIX) Price Target Cut to $143.00 by Analysts at Morgan Stanley

Wix.com (NASDAQ:WIX) Price Target Cut to $143.00 by Analysts at Morgan Stanley

Wix.com (NASDAQ:WIX – Free Report) had its target price decreased by Morgan Stanley from $157.00 to $143.00 in a report issued on Wednesday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the... More of this article »
Image about Tesla (NASDAQ:TSLA) Price Target Lowered to $180.00 at Barclays

Tesla (NASDAQ:TSLA) Price Target Lowered to $180.00 at Barclays

Tesla (NASDAQ:TSLA – Free Report) had its price objective trimmed by Barclays from $225.00 to $180.00 in a research report released on Wednesday, Marketbeat reports. The brokerage currently has an equal weight rating on the electric... More of this article »
Image about AO World (LON:AO) Price Target Raised to GBX 75 at Canaccord Genuity Group

AO World (LON:AO) Price Target Raised to GBX 75 at Canaccord Genuity Group

AO World (LON:AO – Free Report) had its price target raised by Canaccord Genuity Group from GBX 52 ($0.65) to GBX 75 ($0.93) in a research note released on Wednesday, MarketBeat reports. They currently have a sell rating on the... More of this article »
Image about Viracta Therapeutics (NASDAQ:VIRX) Given “Outperform” Rating at Oppenheimer

Viracta Therapeutics (NASDAQ:VIRX) Given “Outperform” Rating at Oppenheimer

Oppenheimer restated their outperform rating on shares of Viracta Therapeutics (NASDAQ:VIRX – Free Report) in a research note released on Wednesday, Benzinga reports. The firm currently has a $13.00 price target on the stock. Separately,... More of this article »
Image about Tesla (NASDAQ:TSLA) Given Outperform Rating at Robert W. Baird

Tesla (NASDAQ:TSLA) Given Outperform Rating at Robert W. Baird

Robert W. Baird reissued their outperform rating on shares of Tesla (NASDAQ:TSLA – Free Report) in a research note published on Wednesday morning, Benzinga reports. Robert W. Baird currently has a $280.00 price objective on... More of this article »
Image about Antofagasta (LON:ANTO) Given “Buy” Rating at Canaccord Genuity Group

Antofagasta (LON:ANTO) Given “Buy” Rating at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Antofagasta (LON:ANTO – Free Report) in a research report sent to investors on Wednesday morning, MarketBeat.com reports. The firm currently has a GBX 1,925 ($23.96)... More of this article »
Image about Take-Two Interactive Software’s (TTWO) Outperform Rating Reaffirmed at Wedbush

Take-Two Interactive Software’s (TTWO) Outperform Rating Reaffirmed at Wedbush

Wedbush restated their outperform rating on shares of Take-Two Interactive Software (NASDAQ:TTWO – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. Wedbush currently has a $190.00 target price... More of this article »
Image about Wingstop (NASDAQ:WING) Price Target Increased to $375.00 by Analysts at Citigroup

Wingstop (NASDAQ:WING) Price Target Increased to $375.00 by Analysts at Citigroup

Wingstop (NASDAQ:WING – Free Report) had its price target raised by Citigroup from $320.00 to $375.00 in a report released on Wednesday, Benzinga reports. Citigroup currently has a neutral rating on the restaurant operator’s... More of this article »
Image about Victory Capital (NASDAQ:VCTR) Price Target Raised to $55.00 at BMO Capital Markets

Victory Capital (NASDAQ:VCTR) Price Target Raised to $55.00 at BMO Capital Markets

Victory Capital (NASDAQ:VCTR – Free Report) had its price target boosted by BMO Capital Markets from $53.00 to $55.00 in a research note released on Wednesday, Benzinga reports. BMO Capital Markets currently has an outperform... More of this article »
Image about Visteon (NASDAQ:VC) Given New $126.00 Price Target at Guggenheim

Visteon (NASDAQ:VC) Given New $126.00 Price Target at Guggenheim

Visteon (NASDAQ:VC – Free Report) had its target price decreased by Guggenheim from $136.00 to $126.00 in a report issued on Wednesday morning, Benzinga reports. Guggenheim currently has a buy rating on the stock. A number of... More of this article »
Image about Travere Therapeutics’ (TVTX) Outperform Rating Reaffirmed at Wedbush

Travere Therapeutics’ (TVTX) Outperform Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a $13.00 target price on the... More of this article »